Simulations Plus (NASDAQ: SLP) has recently received a number of price target changes and ratings updates:
- 6/18/2026 – Simulations Plus was downgraded by Craig Hallum from “buy” to “hold”. They now have a $18.50 price target on the stock.
- 6/17/2026 – Simulations Plus was downgraded by William Blair from “outperform” to “market perform”.
- 6/13/2026 – Simulations Plus was downgraded by Wall Street Zen from “buy” to “hold”.
- 6/5/2026 – Simulations Plus was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
- 5/21/2026 – Simulations Plus was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
- 5/16/2026 – Simulations Plus was upgraded by Wall Street Zen from “hold” to “buy”.
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
See Also
- Five stocks we like better than Simulations Plus
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Simulations Plus Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus Inc and related companies with MarketBeat.com's FREE daily email newsletter.
